SCHEMBL3532780

SCHEMBL3532780

CCCCc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(OC)c1ccc(-c2noc(=O)[nH]2)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.36
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
PLA2G2A P14555 9/20 0.34
CMKLR1 Q99788 1/20 0.34
PLA2G10 O15496 4/20 0.33
PLA2G1B P04054 4/20 0.33
PLA2G5 P39877 4/20 0.33
AGTR1 P30556 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1387061 0.85 NOTUM (0.39) PPARDPPARA
SCHEMBL3743783 0.82 PPARD (0.38) PPARDPPARAPLA2G2APLA2G10PLA2G1B
SCHEMBL3539539 0.80 PPARD (0.45) PPARGPPARDPPARAPLA2G2APLA2G10
SCHEMBL3532783 0.80 PPARG (0.36) PPARGPPARDPPARAPLA2G2APLA2G10
SCHEMBL3743853 0.80 NPC1 (0.36) PPARDPPARA
SCHEMBL1553626 0.79 MAPT (0.39) PPARGPPARDPPARA
SCHEMBL1554170 0.78 NPC1 (0.43) PPARGPPARDPPARA
SCHEMBL3536049 0.77 PPARD (0.42) PPARGPPARDPPARAPLA2G2APLA2G10
SCHEMBL3743839 0.76 PPARD (0.42) PPARGPPARDPPARA
SCHEMBL3538137 0.74 PPARD (0.42) PPARGPPARDPPARAPLA2G2APLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
EP-2083006-A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2009-07-29 EP disclosed
EP-1740583-B1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
EP-1740583-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS Sanofi-Aventis Deutschland GmbH (DE) 2007-01-10 EP disclosed
WO-2005097786-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS PPARD, PPARA, PPARG PPARG 3/4885PPARD 1/4885PPARA 2/4885
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PPARG 2/4885PPARD 1/4885PPARA 3/4885
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PPARG 2/4885PPARD 1/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.